Prognostic factors in patients with advanced non-small cell lung cancer after long-term Anti-PD-1 therapy (HOT1902)

Ito, Shotaro; Asahina, Hajime; Honjo, Osamu; Tanaka, Hisashi; Honda, Ryoichi; Oizumi, Satoshi; Nakamura, Keiichi; Takamura, Kei; Hommura, Fumihiro; Kawai, Yasutaka; Ito, Kenichiro; Sukoh, Noriaki; Yokoo, Keiki; Morita, Ryo; Harada, Toshiyuki; Takashina, Taichi; Goda, Tomohiro; Dosaka‐Akita, Hirotoshi; Isobe, Hiroshi

doi:10.1016/j.lungcan.2021.04.011

Cited by 9 publications

(12 citation statements)

References 31 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Patients who received initial ICI therapy for >1 year without progressive disease were classified as the long-term treatment (LT) group; others were classified as the non-long-term treatment (NLT) group ( 8 ). Drug efficacy was assessed every 8–12 weeks based on the Response Evaluation Criteria in Solid Tumors (RECIST, version 1.1) by computed tomography (CT) scan ( 9 ).…”

Section: Methodsmentioning

confidence: 99%

Eosinophil and IFN-γ associated with immune-related adverse events as prognostic markers in patients with non-small cell lung cancer treated with immunotherapy

Zhang

et al. 2023

Front. Immunol.

View full text Add to dashboard Cite

ObjectivesImmune checkpoint inhibitors (ICIs) alone or combined with other antitumor agents are largely used in lung cancer patients, which show both positive effects and side effects in particular subjects. Our study aims to identify biomarkers that can predict response to immunotherapy or risk of side effects, which may help us play a positive role and minimize the risk of adverse effects in clinical practice.MethodsWe retrospectively collected data from patients with advanced non-small cell lung cancer (NSCLC) treated with ICIs at our center. Patients who received initial ICI therapy for >1 year without progression of disease were classified as long-term treatment (LT) group, while others were classified as the non-long-term treatment (NLT) group. Multivariate logistic analysis was performed to identify independent risk factors of progression-free survival (PFS) and immune-related adverse events (irAEs).ResultsA total of 83 patients (55.7%) had irAEs. The median PFS for patients in grades 1–2 of irAEs vs. grades 3–4 vs non-irAEs groups was (undefined vs. 12 vs. 8 months; p = 0.0025). The 1-year PFS rate for multisystem vs. single vs. non-irAE groups was 63%, 56%, and 31%, respectively. Signal transduction of inflammatory cytokines improves clinical prognosis through immunomodulatory function, but the benefit is also limited by the resulting organ damage, making it a complex immune balance. Serum biomarkers including EOS% of ≥ 1.15 (HR: 8.30 (95% CI, 2.06 to 33.42); p = 0.003) and IFN-γ of ≥ 3.75 (HR: 5.10 (95% CI, 1.29 to 20.15), p = 0.02) were found to be predictive for irAEs.ConclusionEOS% of ≥1.15% and IFN-γ of ≥3.75 ng/L were considered peripheral-blood markers for irAEs and associated with improved clinical outcomes for immunotherapy in patients with advanced NSCLC.

show abstract

Section: Methodsmentioning

confidence: 99%

Eosinophil and IFN-γ associated with immune-related adverse events as prognostic markers in patients with non-small cell lung cancer treated with immunotherapy

Zhang

et al. 2023

Front. Immunol.

View full text Add to dashboard Cite

show abstract

“…We only collected information for irAEs that caused treatment discontinuation. For more information on this study, please see our previous article 21 …”

Section: Methodsmentioning

confidence: 99%

“…In a previous study, we retrospectively examined prognostic factors in patients with advanced NSCLC after long‐term anti‐PD‐1 therapy 21 . Numerous elderly patients were enrolled in that study.…”

Section: Introductionmentioning

confidence: 99%

Real‐world data on the efficacy and safety of immune‐checkpoint inhibitors in elderly patients with non‐small cell lung cancer

et al. 2023

Self Cite

View full text Add to dashboard Cite

Purpose Immune‐checkpoint inhibitors (ICIs) are effective against advanced non‐small cell lung cancer (NSCLC). However, whether the efficacy and safety of ICI treatment in elderly patients are similar to those in younger patients is unclear. This study was designed to address this question. Methods We enrolled patients who received ICI monotherapy in Japan between December 2015 and December 2017; those ≥75 years of age comprised the elderly group. We compared the efficacy and safety of ICI monotherapy in elderly patients with those in younger patients and explored prognostic factors in elderly patients. Results We enrolled 676 patients; 137 (20.3%) were assigned to the elderly group. The median age of the elderly and younger groups was 78 (range, 75–85) and 66 (range, 34–74) years. The median progression‐free survival (4.8 months vs. 3.3 months, p = 0.1589) and median overall survival (12.3 months vs. 13.0 months, p = 0.5587) were similar between the elderly and younger groups. Multivariate analysis revealed that a significantly better OS in the elderly group was associated with better responses to first‐ or second‐line ICI treatment (p = 0.011) and more immune‐related adverse events (irAEs) (p = 0.02). IrAEs that led to ICI discontinuation occurred in 34 of 137 patients (24.8%) in the elderly group, and their survival was significantly higher than that in those who did not have irAEs. Conclusion ICI is also effective in elderly NSCLC patients, and treatment discontinuation due to irAEs may be a good prognostic marker.

show abstract

“…Many patients receiving conventional anti-cancer drugs have to discontinue treatment due to progressive disease (PD) or intolerability to drug toxicities, and the survival rate in these patients is almost 0%. In contrast, tumor-inhibitory effects by ICIs have been reported to persist over a long period in small proportions (approximately 10-20%) of patients with lung cancer (7), malignant melanoma (8), kidney cancer (9) (10). We herein report our investigation of the five-year outcomes in long-term responders for over two years to evaluate the optimal duration of therapy with nivolumab.…”

mentioning

confidence: 95%

Five-year Follow-up of Patients With Head and Neck Cancer Treated With Nivolumab and Long-term Responders for Over Two Years

Matsuo

Yasumatsu

Masuda

et al. 2022

In Vivo

View full text Add to dashboard Cite

Prognostic factors in patients with advanced non-small cell lung cancer after long-term Anti-PD-1 therapy (HOT1902)

Cited by 9 publications

References 31 publications

Eosinophil and IFN-γ associated with immune-related adverse events as prognostic markers in patients with non-small cell lung cancer treated with immunotherapy

Eosinophil and IFN-γ associated with immune-related adverse events as prognostic markers in patients with non-small cell lung cancer treated with immunotherapy

Real‐world data on the efficacy and safety of immune‐checkpoint inhibitors in elderly patients with non‐small cell lung cancer

Five-year Follow-up of Patients With Head and Neck Cancer Treated With Nivolumab and Long-term Responders for Over Two Years

Contact Info

Product

Resources

About